

08 APRIL 2026

ASX RELEASE

AMPLIA MD RESPONDS TO QUESTIONS REGARDING AMPLICITY TRIAL

HIGHLIGHTS AS REPORTED IN COMPANY'S ANNOUNCEMENT DATED 7 April 2026:

- *Recruitment to the AMPLICITY trial has been halted after three Dose Limiting Toxicities (DLTs) related to the chemotherapy regimen mFOLFIRINOX*
- *No toxicity concerns have been identified regarding narmafotinib*
- *Patients already on trial will remain on study and continue treatment*

Melbourne, Australia: Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), ("Amplia" or the "Company"), provides a video response by its Managing Director to questions received from shareholders regarding the Company's announcement on 7 April 2026¹ that it was halting further recruitment in the AMPLICITY clinical trial in advanced pancreatic cancer investigating the Company's lead drug narmafotinib in combination with the chemotherapy regimen modified FOLFIRINOX (mFOLFIRINOX).

The Managing Director's video response can be found here: <https://ampliatx.com/activity-updates/PRKRky-ceo-answers-shareholder-questions>

This ASX announcement was approved and authorized for release by the Managing Director of Amplia Therapeutics.

Investor Contact:

Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com

U.S. Contact:

Robert Giordano
rjgiordano@ggrouplifesciences.com
+1 917 327 3938

Media Contact:

Tom Trezona, H[^]CK Acting MD
tom@hck.digital
+61 411 235 692

U.S. Media:

media@ampliatx.com

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic

¹ ASX Announcement: "Amplia Therapeutics Halts Recruitment in Amplicity Trial", 7 April 2026

pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on [X](#) (@ampliatx) and [LinkedIn](#).

About Narmafotinib

Narmafotinib (AMP945) is the company's best-in-class inhibitor of the protein FAK, a protein over-expressed in pancreatic cancer and a drug target gaining increasing attention for its role in solid tumors. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies. Narmafotinib is currently undergoing a clinical trial (the [ACCENT](#) trial) where it is dosed in combination with the chemotherapies gemcitabine and Abraxane in first-line patients with advanced pancreatic cancer. The trial has already achieved its desired outcome in achieving a response rate of 36%, superior to chemotherapy alone and an interim PFS of 7.7 months has been reported. A second trial – AMPLICITY – is being run under an IND investigating the combination of narmafotinib with the chemotherapy FOLFIRINOX in advanced pancreatic cancer patients.